Deltex Injunction Demonstrates Need For Fast Response To FDA Inspections
This article was originally published in The Tan Sheet
Executive Summary
An injunction prohibiting Deltex Pharmaceuticals from making drugs until it complies with good manufacturing practices and other regulations reminds firms that "the leash may not be as long" under the current FDA as in the past, a health care attorney says.